Obesity drug deal: Novo Nordisk agreed to pay Hengrui Pharma up to US$2.6bn for HRS-1596, a once-weekly oral GLP-1/GIP dual agonist candidate aimed at obesity and type 2 diabetes, with a US$300m upfront and milestones/royalties; the deal excludes mainland China, Hong Kong, Macao and Taiwan. Muscle-sparing weight loss: Regeneron reported Phase 2 COURAGE results showing trevogrumab helped prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss (presented at EASD and in press with The Lancet). Food safety alert (Macao): The Municipal Affairs Bureau ordered a recall of “Familie” Black Truffle Sauce Natural Truffle 5% after testing found excessive total arsenic; residents are urged to stop eating the affected batch. Local healthcare access: Macao Union Medical Center outlined holiday service arrangements for National Day period—outpatient and some services closed, while emergency/inpatient/hemodialysis continue. Hospital operations: The Hospital Authority held a flag-raising ceremony for the 77th PRC anniversary, with staff and leadership marking the occasion. Public health & safety: A taxi failed to give way in a Macao crash, injuring a motorcyclist who was taken to Conde de São Januário Hospital Centre for treatment. Health system workforce (HK): Hong Kong defended hiring policies for non-locally trained nurses, saying they make up less than 0.5% of registered nurses and are mostly short-term exchange staff.